Skip to Content

Sabervel

Active Substance: irbesartan
Common Name: irbesartan
ATC Code: C09CA04
Marketing Authorisation Holder: Pharmathen S.A.
Active Substance: irbesartan
Status: Withdrawn
Authorisation Date: 2012-04-13
Therapeutic Area: Hypertension
Pharmacotherapeutic Group: Agents acting on the renin-angiotensin system

Therapeutic Indication

Sabervel is indicated in adults for the treatment of essential hypertension.

It is also indicated for the treatment of renal disease in adult patients with hypertension and type 2 diabetes mellitus as part of an antihypertensive medicinal product regimen.

The marketing authorisation for Sabervel has expired following the marketing authorisation holder's decision not to apply for a renewal.

Source: European Medicines Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide